| Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer NA Rizvi, MD Hellmann, A Snyder, P Kvistborg, V Makarov, JJ Havel, ... Science 348 (6230), 124-128, 2015 | 8294 | 2015 |
| B cells and tertiary lymphoid structures promote immunotherapy response BA Helmink, SM Reddy, J Gao, S Zhang, R Basar, R Thakur, K Yizhak, ... Nature 577 (7791), 549-555, 2020 | 1869 | 2020 |
| Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer VP Balachandran, M Łuksza, JN Zhao, V Makarov, JA Moral, R Remark, ... Nature 551 (7681), 512-516, 2017 | 1048 | 2017 |
| Emerging concepts for immune checkpoint blockade-based combination therapies R Zappasodi, T Merghoub, JD Wolchok Cancer cell 33 (4), 581-598, 2018 | 545 | 2018 |
| CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors H Wang, F Franco, YC Tsui, X Xie, MP Trefny, R Zappasodi, SR Mohmood, ... Nature immunology 21 (3), 298-308, 2020 | 455 | 2020 |
| Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors S Xu, O Chaudhary, P Rodríguez-Morales, X Sun, D Chen, R Zappasodi, ... Immunity 54 (7), 1561-1577. e7, 2021 | 376 | 2021 |
| A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance AC Huang, R Zappasodi Nature immunology 23 (5), 660-670, 2022 | 310 | 2022 |
| CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours R Zappasodi, I Serganova, IJ Cohen, M Maeda, M Shindo, ... Nature 591 (7851), 652-658, 2021 | 275 | 2021 |
| Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine LF Campesato, S Budhu, J Tchaicha, CH Weng, M Gigoux, IJ Cohen, ... Nature communications 11 (1), 4011, 2020 | 271 | 2020 |
| Rational design of anti-GITR-based combination immunotherapy R Zappasodi, C Sirard, Y Li, S Budhu, M Abu-Akeel, C Liu, X Yang, ... Nature medicine 25 (5), 759-766, 2019 | 216 | 2019 |
| Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce HM Kluger, HA Tawbi, ML Ascierto, M Bowden, MK Callahan, E Cha, ... Journal for immunotherapy of cancer 8 (1), 2020 | 179 | 2020 |
| Non-conventional inhibitory CD4+ Foxp3− PD-1hi T cells as a biomarker of immune checkpoint blockade activity R Zappasodi, S Budhu, MD Hellmann, MA Postow, Y Senbabaoglu, ... Cancer cell 33 (6), 1017-1032. e7, 2018 | 164 | 2018 |
| Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a … M Di Nicola, R Zappasodi, C Carlo-Stella, R Mortarini, SM Pupa, M Magni, ... Blood, The Journal of the American Society of Hematology 113 (1), 18-27, 2009 | 156 | 2009 |
| Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death R Zappasodi, SM Pupa, GC Ghedini, I Bongarzone, M Magni, AD Cabras, ... Cancer research 70 (22), 9062-9072, 2010 | 150 | 2010 |
| Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab L Castagnoli, M Iezzi, GC Ghedini, V Ciravolo, G Marzano, A Lamolinara, ... Cancer research 74 (21), 6248-6259, 2014 | 90 | 2014 |
| The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human … R Zappasodi, M Di Nicola, C Carlo-Stella, R Mortarini, A Molla, C Vegetti, ... haematologica 93 (10), 1523-1534, 2008 | 87 | 2008 |
| Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop D Bedognetti, M Ceccarelli, L Galluzzi, R Lu, K Palucka, J Samayoa, ... Journal for immunotherapy of cancer 7, 1-23, 2019 | 80 | 2019 |
| The new era of cancer immunotherapy: manipulating T-cell activity to overcome malignancy DN Khalil, S Budhu, B Gasmi, R Zappasodi, D Hirschhorn-Cymerman, ... Advances in cancer research 128, 1-68, 2015 | 65 | 2015 |
| Hallmarks of resistance to immune-checkpoint inhibitors M Karasarides, AP Cogdill, PB Robbins, M Bowden, EM Burton, ... Cancer Immunology Research 10 (4), 372-383, 2022 | 56 | 2022 |
| Tumor-Reactive CD8+ Early Effector T Cells Identified at Tumor Site in Primary and Metastatic Melanoma A Anichini, A Molla, C Vegetti, I Bersani, R Zappasodi, F Arienti, ... Cancer research 70 (21), 8378-8387, 2010 | 55 | 2010 |
Taha MerghoubAssociate Professor, MSKEmail verificata su mskcc.org
